Argenica Therapeutics (AGN) Investor presentation summary

Mission, vision, and impact

• Aims to commercialize neuroprotective treatments that minimize brain damage and optimize recovery after stroke and other neurological conditions.

• Seeks to redefine the standard of care for stroke by reducing brain injury and improving outcomes.

• Intends to create life-altering impact for millions suffering from neurological conditions.

Lead asset and mechanism of action

• ARG-007 has shown efficacy in Phase 2 stroke trials, with a clear responder group identified for future studies.

• Demonstrates multiple mechanisms: prevents calcium influx, blocks inflammation, restores mitochondrial function, and stabilizes cell membranes.

• Significant preclinical efficacy in stroke, traumatic brain injury (TBI), and hypoxic ischemic encephalopathy (HIE); supported by 25+ peer-reviewed papers.

Clinical development and indications

• Lead indications include stroke, moderate-severe TBI, HIE, mild TBI, and neurodegeneration.

• Single dose of ARG-007 in severe TBI can move directly from preclinical to Phase 2 trials.

• Positive Phase 2 data in stroke; safety and efficacy established in targeted patient groups.